Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus
Main finding · Composite neonatal outcomeResult — go to the resultAdjusted relative risk 0.92 95% CI 0.81–1.03Authors' conclusion
Our findings were consistent with those reported in the MiTy randomized trial. Continuing metformin during pregnancy was not associated with increased risk of a neonatal composite adverse outcome. However, a possible metformin-associated risk of SGA warrants further consideration.
Study context
- Population
- Pregnant women aged 18–45 years with T2D treated with metformin plus insulin at conception; US claims, 2000–2020; mean age at conception 32 years72% discontinued
- Participants
- 2,983 women
- Exposure
- Continuing vs discontinuing metformin during pregnancy
- Outcome
- Composite of:
- Preterm birth
- Birth injury
- Neonatal respiratory distress
- Neonatal hypoglycemia
- Neonatal ICU admission
Methodological detailsemulation of modified randomized trial (MiTy), two US health care claims databases, adjusted for baseline confounders
- Emulation of modified randomized trial (MiTy)
- Two US health care claims databases
- Adjusted for baseline confounders
Main finding
Composite neonatal outcome
Adjusted relative risk
0.92
95% CI 0.81–1.03
By group
Continuersvs Discontinuers
adjusted RR 0.92 (95% CI 0.81–1.03)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
- Risks similar between treatments and consistent between databases for most secondary outcomes
- Small for gestational age (SGA) elevated in continuers only in the commercially insured population
Original publication
Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes Care. Published 23 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →